Noile-Immune Biotech Inc.

Company Profile

Sector

Healthcare

Industry

Biotechnology

Employees

23

Website

www.noile-immune.com

Country

Japan

Exchange

Tokyo

Minato, Japan

Noile-Immune Biotech researches and develops CAR-T cells for novel cancer immunotherapies. The company's product pipeline includes, NIB101, a target antigen for solid tumors. Its portfolio also includes NIB102, a next-generation CAR-T cell therapy, NIB103, autologous CAR-T cell therapy for mesothelin (MSLN), NIB104, a PRIME technology against target antigens in solid tumors, ADAP01, AUTL01, and CHUG01. Incorporated in 2015, Noile-Immune Biotech is headquartered in Minato, Japan.

Key Stats

52-Week Range

¥114.00¥217.00

Beta0.08

Trailing P/EN/A

Forward P/E-4.66

Trailing EPS-18.33

Avg Volume

Earnings & Analyst

Next EarningsN/A

EPS EstimateN/A

Target Mean Price¥440.00

RecommendationNone

Recommendation MeanN/A

Recent SEC Filings

SEC filings for this ticker are not available yet.